SCHEMBL1263008

SCHEMBL1263008

CCOC(=O)c1cc2c(C=Cc3ccccc3)nn(C(C)OCC)c2s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 10/20 0.50
▸ ALDH1A1 P00352 12/20 0.42
▸ HPGD P15428 11/20 0.42
▸ GLA P06280 1/20 0.42
▸ HSD17B10 Q99714 7/20 0.39
▸ ESR1 P03372 2/20 0.39
▸ TSHR P16473 3/20 0.39
▸ POLB P06746 3/20 0.38
▸ MAPT P10636 5/20 0.38
▸ ADORA3 P0DMS8 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ XBP1 P17861 1/20 0.38
▸ RAB9A P51151 3/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ CASP3 P42574 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1263007 1.00 KDM4E (0.50) KDM4EALDH1A1HPGDGLAHSD17B10
SCHEMBL1262158 0.91 KDM4E (0.42) KDM4EALDH1A1HPGDGLAHSD17B10
SCHEMBL1262155 0.91 KDM4E (0.42) KDM4EALDH1A1HPGDGLAHSD17B10
SCHEMBL6408127 0.84 MAPT (0.37) KDM4EALDH1A1HPGDGLAHSD17B10
SCHEMBL6408124 0.84 MAPT (0.37) KDM4EALDH1A1HPGDGLAHSD17B10
SCHEMBL1262723 0.78 KDM4E (0.47) KDM4EALDH1A1HPGDHSD17B10ESR1
SCHEMBL1263548 0.76 KDM4E (0.45) KDM4EALDH1A1HPGDGLAHSD17B10
SCHEMBL1263492 0.73 HPGD (0.50) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL3322538 0.71 GRM4 (0.46) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL3322543 0.71 GRM4 (0.46) KDM4EALDH1A1HPGDHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884123-B2 3-(1H-indol-2-yl)-1H-thieno[2,3-c]pyrazole-5-(N-phenoxycarboxamide); anticancer agents; protein kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-02-08 — — US disclosed
US-20080058402-A1 Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-03-06 — — US disclosed
US-20050026984-A1 Substituted thieno [2,3-c] pyrazoles and their use as medicinal products AVENTIS PHARMA S.A. (FR) 2005-02-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026984-A1 Substituted thieno [2,3-c] pyrazoles and their use as medicinal products TPMT, PARK7, PRNP KDM4E 3783/4885ALDH1A1 696/4885HPGD 482/4885
US-20080058402-A1 Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof TYMS, TYMP, CYP3A43 KDM4E 3213/4885ALDH1A1 647/4885HPGD 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback